Energy-device maker posts $0.02 earnings beat as U.S. device demand remains steady.
InMode reported Q2 2026 earnings that beat consensus by $0.02 per share, with revenue topping Wall Street estimates. The RF microneedling and energy-device platform maker continues to benefit from steady U.S. aesthetic device demand, though margin compression concerns persist in analyst commentary.
The company's core installed base of Morpheus8 and BodyTite systems remains a revenue anchor, but competitive pressure from Cutera and other multi-modality platforms is intensifying. Steel Partners, InMode's largest shareholder, has publicly urged shareholders to vote against certain governance proposals, signaling activist pressure over capital allocation and strategic direction.
InMode beats EPS by $0.02; margin compression concerns persist.
For practice owners evaluating device ROI, InMode's beat underscores that installed-base revenue and service contracts still drive profitability—but the margin squeeze is real. Watch the next quarter's gross margin trend closely; device-only players without strong recurring revenue models face headwinds.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
